OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis
Xiaoting Huang, Shen Lin, Xin Rao, et al.
Clinical Breast Cancer (2021) Vol. 21, Iss. 4, pp. e479-e488
Closed Access | Times Cited: 14
Xiaoting Huang, Shen Lin, Xin Rao, et al.
Clinical Breast Cancer (2021) Vol. 21, Iss. 4, pp. e479-e488
Closed Access | Times Cited: 14
Showing 14 citing articles:
Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China
Shixian Liu, Kaixuan Wang, Hao Chen, et al.
Cost Effectiveness and Resource Allocation (2025) Vol. 23, Iss. 1
Open Access
Shixian Liu, Kaixuan Wang, Hao Chen, et al.
Cost Effectiveness and Resource Allocation (2025) Vol. 23, Iss. 1
Open Access
Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China
Caifeng Jia, Sen Zhang, Jie Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Caifeng Jia, Sen Zhang, Jie Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) breast cancer: a systematic review
Linhui Zhu, Mengmeng Wang, Xin Luo, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 4, pp. 233-233
Open Access | Times Cited: 17
Linhui Zhu, Mengmeng Wang, Xin Luo, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 4, pp. 233-233
Open Access | Times Cited: 17
Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a systematic review and meta-analysis
Prajakta P. Masurkar, Prachi Prajapati, Joanne Canedo, et al.
Current Medical Research and Opinion (2024), pp. 1-15
Closed Access | Times Cited: 2
Prajakta P. Masurkar, Prachi Prajapati, Joanne Canedo, et al.
Current Medical Research and Opinion (2024), pp. 1-15
Closed Access | Times Cited: 2
CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
Ni Zeng, Jiaqi Han, Zijian Liu, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3386-3386
Open Access | Times Cited: 5
Ni Zeng, Jiaqi Han, Zijian Liu, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3386-3386
Open Access | Times Cited: 5
Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression
Xiaoting Huang, Dong Lin, Shen Lin, et al.
Clinical Breast Cancer (2023) Vol. 23, Iss. 5, pp. 508-518
Closed Access | Times Cited: 3
Xiaoting Huang, Dong Lin, Shen Lin, et al.
Clinical Breast Cancer (2023) Vol. 23, Iss. 5, pp. 508-518
Closed Access | Times Cited: 3
Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis
Qiancheng Hu, Wenli Kang, Qingfeng Wang, et al.
BMJ Open (2022) Vol. 12, Iss. 5, pp. e056374-e056374
Open Access | Times Cited: 4
Qiancheng Hu, Wenli Kang, Qingfeng Wang, et al.
BMJ Open (2022) Vol. 12, Iss. 5, pp. e056374-e056374
Open Access | Times Cited: 4
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer
Juan Hong, Tujia Chen, Ouyang Lihui, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 4, pp. 559-566
Open Access
Juan Hong, Tujia Chen, Ouyang Lihui, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 4, pp. 559-566
Open Access
Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China
Shaohong Luo, Shufei Lai, Yajing Wu, et al.
Strahlentherapie und Onkologie (2024) Vol. 200, Iss. 9, pp. 805-814
Closed Access
Shaohong Luo, Shufei Lai, Yajing Wu, et al.
Strahlentherapie und Onkologie (2024) Vol. 200, Iss. 9, pp. 805-814
Closed Access
Is bevacizumab a cost‑effective regimen for treating cerebral radiation necrosis in the United States?
Shufei Lai, Shaohong Luo, Shen Lin, et al.
Practical Radiation Oncology (2024) Vol. 15, Iss. 1, pp. e10-e20
Closed Access
Shufei Lai, Shaohong Luo, Shen Lin, et al.
Practical Radiation Oncology (2024) Vol. 15, Iss. 1, pp. e10-e20
Closed Access
Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States
Peng Ye, Liting Wang, Liubao Peng, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 10, pp. 965-972
Closed Access
Peng Ye, Liting Wang, Liubao Peng, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 10, pp. 965-972
Closed Access
Cost-effectiveness comparison of dalpiciclib and abemaciclib Combined with an aromatase inhibitor as first-line treatment for HR+/ HER2− advanced breast cancer
Juan Hong, Tujia Chen, Jun Meng, et al.
Research Square (Research Square) (2023)
Open Access
Juan Hong, Tujia Chen, Jun Meng, et al.
Research Square (Research Square) (2023)
Open Access
Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence
Wedad H. Alotaibi, Majd M. Alhamdan, Bander Balkhi
Saudi Pharmaceutical Journal (2022) Vol. 30, Iss. 8, pp. 1113-1119
Open Access
Wedad H. Alotaibi, Majd M. Alhamdan, Bander Balkhi
Saudi Pharmaceutical Journal (2022) Vol. 30, Iss. 8, pp. 1113-1119
Open Access
Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis
Kevin Berrios, Alexandra Burum, Eunae Jeong, et al.
Journal of Managed Care & Specialty Pharmacy (2022) Vol. 28, Iss. 11, pp. 1282-1291
Open Access
Kevin Berrios, Alexandra Burum, Eunae Jeong, et al.
Journal of Managed Care & Specialty Pharmacy (2022) Vol. 28, Iss. 11, pp. 1282-1291
Open Access
